Upcoming event


Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, Emission-computed, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, WCRF/AICR CUP, Wnt, Zoledronic acid
Show all

Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: A network meta-analysis of randomized trials

Journal of Clinical Oncology, May 2020

The impact of race and age on distribution of metastases in patients with prostate cancer

Journal of Urology, May 2020

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)

Annals of Oncology, May 2020

Multi-institutional assessment of routine same day discharge surgery for robot-assisted radical prostatectomy

Journal of Urology, May 2020

Third-line life-prolonging drug treatment in a real-world metastatic castration-resistant prostate cancer population: results from the Dutch castration-resistant prostate cancer registry

European Urology Focus, April 2020

Surgery associated with increased survival compared to radiation in clinically localized Gleason 9–10 prostate cancer: a SEER analysis

World Journal of Urology, April 2020

Olaparib for metastatic castration-resistant prostate cancer

The New England Journal of Medicine, April 2020

Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/ computed tomography in primary prostate cancer diagnosis

European Urology Focus, April 2020

Additional value of dynamic contrast-enhanced sequences in multiparametric prostate magnetic resonance imaging: data from the PROMIS Study

European Urology, April 2020

External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection

European Urology, April 2020

Changes in treatment and mortality in men with locally advanced prostate cancer between 2000‐2016. Nationwide, population‐based study in Sweden

BJU International, April 2020

Competing risks of mortality among men with biochemical recurrence after radical prostatectomy

Journal of Urology, April 2020